Does Humana Cover Saxenda?

Humana Commercial Formulary Status for Saxenda

Saxenda sits on a specialty or non-preferred brand tier on most Humana commercial formularies, when it appears at all. Coverage is not guaranteed. Individual and group plans differ widely, and self-funded employer groups may carve anti-obesity medications out entirely.

Humana updates its formulary quarterly, so a plan that excluded Saxenda in January could add it by April (or vice versa). The most reliable way to confirm your status is to log in to MyHumana and search the formulary tool for "liraglutide 3 mg" under your specific plan ID. If the drug appears with a "PA" or "ST" flag, your plan does cover it subject to prior authorization or step therapy. If it does not appear, your plan excludes it regardless of medical necessity.

Even when Saxenda is listed, cost-sharing can be substantial. Members on a non-preferred brand tier typically face coinsurance of 30% to 50% after their deductible, which on a $1,349 monthly list price translates to $405 to $675 out of pocket per fill 1. That amount may count toward your annual out-of-pocket maximum, but it often takes several months to reach it.

According to the Endocrine Society's 2024 clinical practice guideline on pharmacotherapy for obesity, insurers should cover FDA-approved anti-obesity medications "as part of a comprehensive weight-management program," though this recommendation has not yet been adopted uniformly by commercial payers 2.

Humana Medicare Advantage and Saxenda

Most Humana Medicare Advantage (MA) plans do not cover Saxenda. The reason is federal, not Humana-specific. CMS has historically excluded anti-obesity drugs from the Part D benefit on the basis that they are used for "anorexia, weight loss, or weight gain" (Social Security Act §1862(a)(1)(A)). This exclusion persists even when a prescriber documents a comorbidity such as type 2 diabetes or obstructive sleep apnea.

There is one narrow exception. If a patient carries a diagnosis of prediabetes or cardiovascular risk reduction that an MA plan covers under a supplemental benefit, some Humana MA-PD plans have begun piloting limited anti-obesity drug coverage as a Special Supplemental Benefit for the Chronically Ill (SSBCI). These pilots are plan-year specific and region-limited, so they cannot be assumed.

The Inflation Reduction Act's Part D redesign, which took effect in 2025, capped annual out-of-pocket drug spending at $2,000, but this cap only applies to drugs that Part D actually covers. Because Saxenda remains excluded from the Part D formulary on most MA plans, the $2,000 cap does not help MA enrollees who want Saxenda 3.

For MA members, the practical path is usually to explore alternative GLP-1 receptor agonists that carry a diabetes indication (and thus are covered under Part D), or to use the Novo Nordisk patient assistance program, which may supply Saxenda at no cost to patients with household income below 400% of the federal poverty level.

Prior-Authorization Criteria for Saxenda on Humana

Humana requires prior authorization for Saxenda on every plan that lists it. Approval criteria generally mirror FDA labeling with added utilization-management gates. Expect the following requirements:

Clinical criteria. A documented BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea). The prescriber must submit chart notes showing the BMI was measured within the past 90 days.

Lifestyle documentation. Evidence that the patient has participated in a structured diet and exercise program for at least three to six months before the request. A simple note saying "counseled on diet" is usually insufficient. Humana reviewers look for referral to a registered dietitian, enrollment in a medically supervised weight-management program, or documented caloric targets.

Step therapy. Many Humana commercial plans require trial and failure of at least one lower-cost anti-obesity agent before approving Saxenda. Phentermine (generic, roughly $30 per month) is the most common required first step. Humana defines "failure" as inadequate weight loss (typically <5% of body weight) after 12 weeks at a therapeutic dose, or documented intolerance (adverse effects requiring discontinuation).

Prescriber type. Some plans restrict initial PA submissions to endocrinologists, obesity-medicine specialists, or primary-care physicians with documented obesity-medicine training. This requirement is less common but has appeared in certain Humana employer-group formularies.

The PA is typically valid for 12 months. Renewal requires documentation that the patient has achieved and maintained at least 4% weight loss from baseline; if not, Humana may deny continuation, citing lack of therapeutic response consistent with FDA labeling guidance 1.

How the SCALE Trial Supports Your PA Request

Citing specific efficacy data in the prior-authorization letter strengthens the clinical rationale. The SCALE Obesity and Prediabetes trial (N=3,731) randomized adults with BMI ≥30 (or ≥27 with comorbidity) to liraglutide 3 mg or placebo, both combined with lifestyle intervention. At 56 weeks, the liraglutide group lost 8.0% of body weight compared with 2.6% in the placebo arm (P<0.001). A total of 63.2% of liraglutide-treated patients achieved ≥5% weight loss, versus 27.1% on placebo 4.

The same trial showed a 13-week delay to prediabetes-to-diabetes conversion among patients treated with liraglutide. That finding matters for PA letters because it reframes Saxenda as a preventive intervention, not a cosmetic one. Payers, Humana included, are more receptive to preventive framing.

A 2021 meta-analysis in JAMA Network Open pooled data from five liraglutide 3 mg trials and confirmed a mean placebo-subtracted weight loss of 5.3 kg at 56 weeks, with consistent effects across subgroups defined by baseline BMI, sex, and presence of type 2 diabetes 5. Including this pooled estimate alongside the SCALE primary data demonstrates generalizability, which is precisely what a medical director reviewing a PA wants to see.

Dr. Robert Kushner, professor of medicine at Northwestern University Feinberg School of Medicine and an investigator on the SCALE trial, has stated: "Liraglutide 3 mg addresses the biological drivers of weight regain in a way that behavioral therapy alone cannot sustain over 12 months" 4.

How to Appeal a Humana Denial of Saxenda

Denials are common. Do not treat a first denial as final.

Step 1: Request the denial letter. Humana must provide a written explanation citing the specific clinical policy bulletin and the criteria the patient did not meet. Read it carefully. Many denials cite missing documentation rather than medical inappropriateness, which means a resubmission with additional chart notes may succeed without a formal appeal.

Step 2: File an internal appeal. Humana allows 180 days from the denial date for commercial plans and 60 days for MA plans. The appeal should include a peer-reviewed letter from the prescribing physician, updated BMI documentation, a record of prior treatment failures, and relevant clinical-trial citations (SCALE at minimum). Attach lab work showing any weight-related comorbidity values (HbA1c, lipid panel, liver enzymes). Humana must respond within 30 calendar days for commercial and 7 days for expedited MA requests.

Step 3: External review. If the internal appeal is denied, commercial members can request an independent external review through their state insurance department. This review is binding on Humana. MA members follow a different path: they file with the Medicare Appeals entity (currently MAXIMUS Federal Services), which conducts an Independent Review Entity (IRE) evaluation. The MAXIMUS process has its own 60-day timeline.

The American Medical Association's model appeal letter for anti-obesity medication coverage (available on the AMA PolicyFinder site) is a useful template. Customize it with the patient's specific clinical data rather than submitting a generic form.

According to a 2023 analysis by the Obesity Action Coalition, approximately 40% of initial denials for GLP-1 receptor agonist anti-obesity medications were reversed on first internal appeal when the appeal included peer-reviewed efficacy data and documentation of lifestyle intervention 6.

Step Therapy: What Humana Requires Before Saxenda

Step therapy is Humana's way of ensuring lower-cost options are tried first. The typical sequence looks like this:

Step 1: Phentermine. Generic phentermine (15 mg or 37.5 mg) for at least 12 weeks. Cost is approximately $30 per month. Humana considers this step satisfied if the patient lost <5% body weight or experienced adverse effects such as insomnia, tachycardia, or elevated blood pressure.

Step 2: Phentermine-topiramate ER (Qsymia) or naltrexone-bupropion ER (Contrave). Some Humana plans require a trial of one of these combination agents before advancing to an injectable. Both are oral, lower-cost alternatives. A documented 12-week trial with <5% weight loss or intolerance satisfies this step.

Not every Humana plan enforces all steps. Plans with a "PA only" flag (no "ST" flag) may approve Saxenda after documenting lifestyle intervention alone. Confirm the exact requirements by calling the number on the back of the member's insurance card and requesting the clinical policy bulletin for liraglutide 3 mg.

The Obesity Medicine Association's 2024 algorithm recommends that step-therapy requirements "should not delay access to medications with demonstrated cardiovascular or metabolic benefit when clinically indicated" 7.

Using the Novo Nordisk Savings Card with Humana

Commercially insured Humana members may be eligible for the Novo Nordisk Saxenda Savings Card, which reduces out-of-pocket costs by up to $200 per 30-day fill. The card cannot be combined with government insurance (Medicare, Medicaid, Tricare, VA), so MA members are excluded.

Key restrictions: the savings card typically has an annual maximum benefit (often $3,600 per year), the pharmacy must process the Humana claim first (the card is applied as a secondary discount), and the offer can be modified or withdrawn by Novo Nordisk at any time.

Patients should also ask their prescriber about the Novo Nordisk Patient Assistance Program (PAP). Eligibility is based on household income (generally below 400% FPL), lack of prescription drug coverage, or coverage that explicitly excludes anti-obesity medications. Approved patients receive Saxenda at no cost for up to 12 months, renewable annually 1.

Saxenda vs. Alternatives on Humana Formularies

If Humana denies Saxenda, two alternatives may carry better formulary positioning on the same plan:

Semaglutide 2.4 mg (Wegovy). Wegovy demonstrated 14.9% mean weight loss at 68 weeks in the STEP 1 trial (N=1,961), compared with Saxenda's 8.0% at 56 weeks 8. However, Wegovy faces similar or more restrictive PA requirements on Humana plans and is often on the same specialty tier. Its list price is comparable.

Oral semaglutide 50 mg (Rybelsus, off-label for obesity). Some Humana plans cover Rybelsus for type 2 diabetes. For patients with both obesity and T2D, this may provide a covered path to a GLP-1 receptor agonist, though the obesity-specific dose of oral semaglutide is not yet FDA-approved for weight management as of May 2026.

Tirzepatide (Zepbound). The SURMOUNT-1 trial (N=2,539) showed 20.9% mean weight loss at 72 weeks with the 15 mg dose 9. Zepbound's formulary status on Humana varies, but some commercial plans have added it at a preferred specialty tier following its strong efficacy data.

A prescriber can request a formulary exception if a covered alternative is contraindicated or has been tried and failed. This is a distinct process from a standard PA and requires a separate letter documenting why the specific alternative is not appropriate for the patient.

What Happens if You Lose Coverage Mid-Treatment

Abrupt discontinuation of liraglutide 3 mg is associated with weight regain. In the SCALE Maintenance trial extension, patients who stopped liraglutide regained an average of 2.9 kg over the following 12 weeks, compared with 0.3 kg of additional loss in those who continued 4. If your Humana coverage changes (job change, plan-year formulary update, move to an MA plan), plan for continuity before the gap occurs. Options include requesting a 90-day bridge supply through your current plan, enrolling in the Novo Nordisk PAP during the transition, or working with your prescriber to switch to a covered alternative with an overlap taper.